NBO (acronym for Nasal Bioavailability of Octreotide) Pharma Inc. was incorporated in 2021 to develop a drug for the treatment of Idiopathic Intracranial Hypertension [IIH] for which no drugs are approved. We are re-purposing an existing orphan drug – octreotide acetate – with an Intranasal [IN] formulation. IN octreotide is undergoing clinical trials for IIH.